Rheumatology

JHL Biotech Doses First Patients in Denosumab Trial

May 19th 2020

By Tony Hagen

Taiwan-based JHL Biotech said it has initiated a phase 1 clinical trial of its denosumab biosimilar candidate for bone loss.

AstraZeneca Quietly Acknowledges Receipt of Brazikumab

May 16th 2020

By Tony Hagen

Article

If it has strong intentions to develop the IL-23 agent brazikumab for commercialization, AstraZeneca did not show its hand when it acknowledged receipt of the agent from Allergan last week.

Alvotech Reports Efficacy and PK Results for AVT02

May 14th 2020

By Tony Hagen

Article

Icelandic company Alvotech said clinical trials for its adalimumab candidate have demonstrated equivalence to reference product Humira.

Celltrion Says It Will Waste No Time in Launching CT-P17

May 13th 2020

By Tony Hagen

Article

Celltrion is pinning its hopes on a higher-concentration formulation of adalimumab to gain elbow room among multiple competing products.

Formycon Postpones Annual Meeting Due to COVID-19

May 12th 2020

By Skylar Jeremias

Article

German biopharmaceutical company Formycon has postponed its annual meeting due to the coronavirus disease 2019 (COVID-19) pandemic.

Udenyca Biosimilar Drives Growth for Coherus Biosciences

May 9th 2020

By Skylar Jeremias

Article

Coherus Biosciences, of Redwood City, California, sees continued profitability, thanks largely to sales of its pegfilgrastim biosimilar, Udenyca, launched in January 2019.

AbbVie, Allergan Merger Puts IL-23 Inhibitor Competition in Doubt

May 7th 2020

By Tony Hagen

Article

The Federal Trade Commission was deeply divided over whether the AbbVie-Allergan $63 billion merger plan would allow for a sufficiently competitive marketplace.

Gedeon Richter Buys Mycenax's Tocilizumab Biosimilar

May 5th 2020

By Skylar Jeremias

Article

Interest in tocilizumab has grown lately as Roche has a clinical trial underway to evaluate efficacy in coronavirus disease 2019 (COVID-19)–related pneumonia.

Teva, Celltrion Maintain Slender Discount to Rituxan

May 4th 2020

By Tony Hagen

Article

Although Pfizer has offered a more attractive discount for its rituximab biosimilar, Teva Pharmaceutical Industries and Celltrion Healthcare have decided not to match that discount for their own rituximab biosimilar, which is more costly.

New Zealand Study Reveals Importance of Patient Attitudes Toward Biosimilars

April 24th 2020

By Tony Hagen

Article

A New Zealand study of patients with rheumatic conditions suggests that providers need to be mindful of patient attitudes toward biosimilars to prevent biased therapy choices and poor outcomes.